2021 - Effective Genotoxic Impurities Assessment In Drug Development

OVERVIEW
Residual impurities resulting from the synthetic route, the formulation, or from the degradation of the active drug and/or the excipients, may be present in the pharmaceutical products that will be administered to patients. Some of these impurities may present a potential for genotoxicity and therefore pose an additional safety concern to clinical subjects and patients. When genotoxic impurities are detected, these should be controlled and limited, if not avoided, in the final product to ensure the safety of the patients. During drug development, the strategies to control all impurities at safe concentrations are mandatory and regulated by ICH guidelines that are adopted worldwide. However, the effort made to limit impurities must be commensurate with the risk assessed at each phase of clinical development and thereafter for marketing. The webinar provides a general overview of the topic of genotoxic impurities and the approaches to safety evaluations.
WHY SHOULD YOU ATTEND?
An effective evaluation of potential genotoxic impurities is essential for the overall success of any drug development program for small molecules. In this webinar we will focus on the basics for an effective genotoxic impurities assessment. A case study will be described to further provide a focus on the concepts discussed.
AREA COVERED
Understanding the difference between genotoxicity and mutagenicity
Recognize the importance of genotoxic impurities evaluations in drug development
Learn the necessary steps to assess the toxicological profiles of impurities
Learn the concept of the toxicological threshold for concern (TTC)
Learn the concept of Permitted Daily Allowance
Influence and motivate cross-functional colleagues to embrace their critical roles in successful genotoxic impurities evaluation programs
WHO WILL BENEFIT?
Project Managers
Regulatory Affairs
Pharmaceutical Development Scientists
Toxicologists
Drug Discovery Scientists
CMC Scientists
Clinical Development Scientists
SPEAKER PROFILE
Dr. Stefano Persiani is within the Internal & External Innovation, Director of Translational Sciences and Pharmacokinetics at Rottapharm Biotech, Italy since the year 2000. Dr. Persiani received his Ph.D. in Pharmacy from the University of Milan, in Italy and completed his Post-Doctoral fellowship in the Department of Pathology of the University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
For more detail, please click on this below link:
https://bit.ly/3oxMFAf
Email: info-AT-247compliance.us
Tel: +1-661-336-9555
Follow Us: https://www.linkedin.com/in/whitney-jones-87357317...